相关实验视频
Updated: Mar 10, 2026

08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
41.8K
鲁他卡因调节NF-κB通路,减轻小鼠卵胺诱导的喘
1Department of Pediatric Respiratory Medicine, Nanyang Central Hospital (Nanyang Maternal and Child Health Care Hospital), Nanyang, China.
Chemical biology & drug design
|March 9, 2026
概括
鲁他卡 (RUT) 通过减少呼吸道炎症,重塑和氧化应激,有效治疗儿科喘. 这种天然化合物通过抑制核因子-卡帕B (NF-κB) 途径而起作用,为喘治疗提供了潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 儿童喘涉及呼吸道炎症,重塑和氧化应激.
- 鲁他卡 (RUT) 是一种生物活性化物,在过敏性疾病中表现有前途.
- 在喘中RUT的治疗效果和机制尚不清楚.
研究的目的:
- 在卵胺 (OVA) 诱导的喘小鼠模型中研究鲁泰卡尔 (RUT) 的疗效.
- 阐明RUT在喘中的作用的潜在分子机制.
主要方法:
- 建立了一个由OVA诱导的小鼠喘模型.
- 在10和20毫克/公斤的剂量中使用RUT.
- 评估了肺炎评分,细胞因子水平 (IL-4,IL-5,IL-13),支气管洗液 (BALF) 中的细胞计数,气道重塑标记 (α-平滑肌动蛋白,I型原),粘液过分分泌,氧化损伤和NF-κB通路激活.
主要成果:
- RUT显著降低了肺炎得分 (37.5%和50.0%分别在10和20毫克/公斤).
- 在BALF中,RUT抑制了关键的炎症性细胞因子 (IL-4,IL-5,IL-13) 和炎症细胞透.
- RUT降低了呼吸道改造的标记物,改善了粘液的过分分泌,保护了氧化损伤,并抑制了NF-κB激活.
结论:
- 在儿童喘中,RUT在减轻炎症,呼吸道重塑和氧化应激方面显示出显著的治疗潜力.
- 对NF-κB通路的抑制作用是RUT有效性的关键机制.
- 作为儿科喘的辅助疗法,RUT显示出有希望的结果,这需要进一步的临床研究.
相关概念视频
NF-κB-dependent Signaling Pathway
10.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
10.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K

